spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:   PsA  

 HSMN NewsFeed - 26 May 2026
Olympus to Acquire BioProtect to Expand Its Portfolio of Urological Technologies and Address Prostate Cancer
Devices Urology Oncology Mergers & Acquisitions
 HSMN NewsFeed - 3 Jul 2025
Novartis Provides Update on Phase III GCAptAIN Study of Cosentyx(R) in Giant Cell Arteritis (GCA)
Biopharmaceuticals
 HSMN NewsFeed - 30 May 2025
Isotopia and Cardirad Announce Launch of Isoprotrace(R) in Sweden and Denmark, Expanding Access to Advanced Prostate Cancer Imaging
Biopharmaceuticals Radiology Oncology Product Launch
 HSMN NewsFeed - 25 Apr 2025
FDA Clears New Clarius Prostate AI To Help Physicians Assess and Diagnose Common Urologic Conditions in Minutes
Devices Urology FDA
 HSMN NewsFeed - 23 Sep 2024
UCB Announces U.S. FDA Approvals for BIMZELX(R) (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Mar 2024
Astellas Receives Positive CHMP Opinion for XTANDI(TM) in Additional Recurrent Early Prostate Cancer Treatment Setting
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 31 Oct 2023
FDA Approves Novartis Cosentyx(R) as the First New Biologic Treatment Option for Hidradenitis Suppurativa Patients in Nearly a Decade
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 May 2022
RadNet Artificial Intelligence Subsidiaries, DeepHealth and Quantib, Obtain FDA Clearance for Mammography and Prostate AI Tools
Devices Radiology FDA
 HSMN NewsFeed - 7 Feb 2022
US FDA "Study May Proceed" Letter for Clarity's Cu-64 SAR-bisPSMA Trial in Prostate Cancer
Biopharmaceuticals Diagnostics Oncology FDA
 HSMN NewsFeed - 24 Aug 2021
European Commission Approves RINVOQ(R) (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 11 Dec 2020
CHMP Recommends the Approvals of RINVOQ(TM) (Upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 6 Nov 2020
XTANDI(R) (enzalutamide soft capsules) Approved by China NMPA for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Jul 2020
TREMFYA(R) (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 May 2020
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Nov 2019
INHIBITOR Therapeutics Submits Investigational New Drug Application for Treatment of Patients with Late-Stage Prostate Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Nov 2019
ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz(R) (ixekizumab) Versus Humira(R) (adalimumab) Trial in Psoriatic Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 18 Oct 2019
AbbVie Receives CHMP Positive Opinion for Upadacitinib (RINVOQ(TM)) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 Aug 2019
Sophiris Bio Announces Completion of $4.0 Million Registered Direct Offering
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 14 Jun 2019
Janssen reports top-line Phase 3 results for TREMFYA(R) (guselkumab) in adults with active psoriatic arthritis
Biopharmaceuticals
 HSMN NewsFeed - 14 Jun 2019
Lilly Presents Positive Results for Taltz(R) (ixekizumab) vs. Humira(R) (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology
Biopharmaceuticals
 HSMN NewsFeed - 28 May 2019
True Diagnostics, Inc. Receives FDA 510(k) Clearance to Market VeriClear(TM) Digital Test Device for Early Result Pregnancy
Diagnostics FDA
 HSMN NewsFeed - 29 Apr 2019
U.S. FDA Accepts New Drug Application and Grants Priority Review for Darolutamide
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Feb 2019
AbbVie Announces New Drug Application Accepted for Priority Review by U.S. FDA for Upadacitinib for Treatment of Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Dec 2018
Lilly Announces Positive Top-Line Results for Taltz(R) (ixekizumab) vs. Humira(R) (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 3 Oct 2018
Trovagene Announces Exclusive License Agreement with MIT for Combination Therapy of Anti-Androgens and Polo-like Kinase Inhibitors in Prostate Cancer
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 25 Sep 2018
Largest Prostate SBRT Studies to Date Show Accuray CyberKnife(R) System Provides Excellent Prostate Cancer Survival Rates in Five or Fewer Sessions
Devices Oncology
 HSMN NewsFeed - 16 Jan 2018
Novartis new data reinforces superiority of Cosentyx(R) versus Stelara(R) in achieving skin clearance for psoriasis patients
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 8 Nov 2017
Long-Term Use of Lilly's Taltz(R) (ixekizumab) Shows Efficacy Improvements in Psoriatic Arthritis for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors
Biopharmaceuticals
 HSMN NewsFeed - 11 Oct 2017
Janssen Submits New Drug Application to U.S. FDA for Apalutamide (ARN-509) to Treat Men with Non-Metastatic Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Sep 2017
IsoRay Announces "Long-term PSA Outcomes in a Single Institution, Prospective Randomized Cesium-131 / Iodine-125 Permanent Prostate Brachytherapy Trial" Poster Presentation at 2017 Annual American Society for Radiation Oncology (ASTRO) Conference
Devices Oncology
 HSMN NewsFeed - 14 Sep 2017
Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jul 2017
Churchill Pharmaceuticals Announces NDA Filing Acceptance for YONSA(TM) by the U.S. FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Jun 2017
EULAR 2017: Lilly's Taltz(R) (ixekizumab) Demonstrated No Progression or Minimal Progression of Radiographic Disease in Patients with Psoriatic Arthritis Through 52 Weeks
Biopharmaceuticals
 HSMN NewsFeed - 19 May 2016
Decipher Prostate Cancer Test Guides Timing of Postoperative Radiotherapy
Diagnostics Devices Oncology
 HSMN NewsFeed - 5 Apr 2016
Pfizer Announces Positive Top-Line Results from the First Phase 3 Trial of Investigational Tofacitinib in Adults with Psoriatic Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 10 Mar 2016
ProMark(R) Prostate Cancer Prognostic Now Included in NCCN Guidelines
Diagnostics Oncology
 HSMN NewsFeed - 4 Feb 2016
GenomeDx Publishes First Study Supporting Use of Decipher Test in Prostate Biopsy
Diagnostics Oncology
 HSMN NewsFeed - 25 Jan 2016
Steba Biotech Completes its European Phase 3 Clinical Trial of TOOKAD(R) in Patients with Low-Risk Prostate Cancer and Submits Marketing Authorization Application to the European Medicine Agency
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 16 Jan 2016
Novartis receives two new FDA approvals for Cosentyx(R) (secukinumab) to treat patients with ankylosing spondylitis and psoriatic arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Nov 2015
New CyberKnife(R) and TomoTherapy(R) System Data Presented at Leading Scientific Industry Meeting
Devices Oncology
 HSMN NewsFeed - 15 Oct 2015
GenomeDx Biosciences Adds Tina Nova and Craig Johnson to Board of Directors
Diagnostics Personalized Medicine Oncology Personnel
 HSMN NewsFeed - 12 Oct 2015
Teva Announces Exclusive Launch of Generic Avodart(R) Capsules in the United States
Biopharmaceuticals Urology Generics Product Launch
 HSMN NewsFeed - 5 Oct 2015
Precision Biopsy Raises $33.6 Million to Accelerate the Commercial Expansion of its ClariCore(TM) Biopsy System
Devices Urology Venture Capital
 HSMN NewsFeed - 16 Sep 2014
Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Jul 2014
Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer
Biopharmaceuticals Diagnostics Oncology Licensing
 HSMN NewsFeed - 3 Mar 2014
Myriad Publishes Clinical Utility Study for Prolaris(R)
Diagnostics Urology
 HSMN NewsFeed - 11 Feb 2014
Tokai Pharmaceuticals Appoints John McBride as Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 29 Jan 2014
Myriad's Prolaris(R) Test Significantly Modifies Treatment Decisions for Patients With Prostate Cancer
Diagnostics Oncology
 HSMN NewsFeed - 3 Jan 2014
Metabolon Closes $15 Million Series E Financing
Diagnostics Venture Capital Personnel
 HSMN NewsFeed - 4 Dec 2013
Myriad's Prolaris(R) Test Guides Treatment Decisions for Men with Prostate Cancer
Diagnostics Urology Oncology
 HSMN NewsFeed - 30 Sep 2013
Cimzia(R) (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Jun 2013
First Head-to-Head Study Shows Greenlight XPS(R) Laser Therapy Equally Safe and Effective with Faster Recovery as Commonly Used Turp for Treatment of BPH
Devices Urology
 HSMN NewsFeed - 15 May 2013
Tokai Pharmaceuticals Announces $35.5 Million Series E Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 7 May 2013
ASTRO and AUA Issue Joint Guideline for Radiation Therapy After Prostatectomy
Devices Urology Oncology
 HSMN NewsFeed - 14 Mar 2013
EDAP Introduces Focal.One(R): A New Robotic HIFU Device for Focal Therapy of Prostate Cancer
Devices Oncology Product Launch
 HSMN NewsFeed - 24 Jul 2012
Debiopharm Group(TM) - First Patient Treated in Phase III Study With Subcutaneous Administration of Debio 8206 for Treatment of Advanced Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Jun 2012
Abbott Presents Phase 3 Study Results for Investigational Use of HUMIRA(R) (Adalimumab) in Patients with Active Peripheral Spondyloarthritis
Biopharmaceuticals
 HSMN NewsFeed - 7 May 2012
IsoRay to Introduce GliaSite and Cesium-131 Mesh to International Audience at World Congress of Brachytherapy
Devices Oncology
 HSMN NewsFeed - 6 Mar 2012
Aragon Pharmaceuticals Secures $42 Million in Series C Financing to Advance Pipeline of Therapies Targeting Hormone-Driven Cancers
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 28 Feb 2012
FIRMAGON(R) (degarelix) demonstrates non-inferiority to goserelin with bicalutamide in reducing prostate volume in prostate cancer patients while providing better relief from lower urinary tract symptoms
Biopharmaceuticals Urology Oncology
 HSMN NewsFeed - 15 Feb 2012
FDA Approves Gen-Probe's PROGENSA(R) PCA3 Assay, First Urine-Based Molecular Test to Help Determine Need for Repeat Prostate Biopsies
Diagnostics FDA
 HSMN NewsFeed - 20 Jan 2012
Remicade(R) (Infliximab) Receives Positive Opinion From CHMP In Europe for Treatment of Ulcerative Colitis in Pediatric Patients
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 14 Oct 2011
Health Discovery Corporation Agrees with the U.S. Preventive Services Task Force’s Position Against PSA-Based Screening for Prostate Cancer and Believes Its Four-Gene Assay for Prostate Cancer is the Best Alternative to PSA
Diagnostics Personalized Medicine Oncology
 HSMN NewsFeed - 30 Aug 2011
Accuray Drives Growth in Radiosurgery for Early-Stage Prostate Cancer
Devices Oncology
 HSMN NewsFeed - 24 Aug 2011
Masimo Obtains CE Mark for SEDLine, Launches EEG-Based Brain Function Monitors in European Market
Devices Monitoring
 HSMN NewsFeed - 20 Jun 2011
Abbott Receives FDA Approval for a New Six-Month Formulation of Lupron Depot(R) (leuprolide acetate for depot suspension) for the Palliative Treatment of Advanced Prostate Cancer
Biopharmaceuticals Drug Delivery Oncology FDA
 HSMN NewsFeed - 8 Jun 2011
FDA Approves Trial of Adamis Pharmaceuticals Product Candidate to Treat Prostate Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Feb 2011
BIOTRONIK Introduces New Unique Reliaty Pacing System Analyzer
Devices Cardiology
 HSMN NewsFeed - 18 Jan 2011
PrognosDx Announces Appointments of Dr. Garry Nolan to Board of Directors and Dr. Joseph Presti to Scientific Advisory Board
Diagnostics Oncology Personalized Medicine Personnel
 HSMN NewsFeed - 13 Dec 2010
XGEVA (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Dec 2010
Bavarian Nordic Receives Special Protocol Assessment Agreement From the FDA for Phase 3 Trial of PROSTVAC(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Oct 2010
Abiraterone Acetate Significantly Improved Overall Survival for Patients with Metastatic Advanced Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Oct 2010
Phase III Data Showing Improved Survival With Jevtana(R) (cabazitaxel) Injection in Second-Line Advanced Prostate Cancer Published in The Lancet
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Aug 2010
Radient Pharmaceuticals Appoints Gary Giarratano as Director of North American Sales and Marketing
Diagnostics Personalized Medicine Oncology Personnel
 HSMN NewsFeed - 29 Apr 2010
Bavarian Nordic Receives FDA Fast Track Designation for PROSTVAC(TM)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Mar 2010
AUA Responds to American Cancer Society Guideline for the Early Detection of Prostate Cancer
Diagnostics Oncology
 HSMN NewsFeed - 25 Feb 2010
Adamis Pharmaceuticals Signs Agreement to Acquire Prostate Cancer Drug Candidates
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 4 Dec 2009
Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Dec 2009
Fighting Prostate Cancer With Speed and Accuracy: RapidArc(R) Radiotherapy Available at the Delaware Valley Urology Cancer Treatment Center
Devices Oncology
 HSMN NewsFeed - 19 Oct 2009
New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 19 Oct 2009
New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 6 Oct 2009
SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 1 Oct 2009
Prostate Cancer Study Results Published on Patients Treated With CyberKnife Radiosurgery
Devices Urology Oncology
 HSMN NewsFeed - 4 Aug 2009
Ferring Pharmaceuticals Announces Trade Name FIRMAGON(R) (degarelix for injection) for Advanced Prostate Cancer Treatment
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Jul 2009
Allostera Pharma Inc. Closes $17M (CAD) Series A Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 26 Jun 2009
SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 1 Jun 2009
PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Apr 2009
OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Apr 2009
CyberKnife Radiosurgery Used to Treat More Than 3,000 Prostate Cancer Patients Worldwide
Devices Oncology
 HSMN NewsFeed - 1 Apr 2009
Doctors at Henry Ford Health System Treat Ovarian, Prostate, Lung, and Other Forms of Cancer Using Novalis Tx(TM) Platform for Image-Guided Radiosurgery
Devices Oncology
 HSMN NewsFeed - 31 Mar 2009
Stanford Study on CyberKnife Radiosurgery for Prostate Cancer Demonstrates 100 Percent PSA Response at 33 months
Devices Oncology
 HSMN NewsFeed - 18 Mar 2009
FIRMAGON(R) (Degarelix) is Launched in Europe for the Treatment of Advanced Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Mar 2009
Ferring Pharmaceuticals Announces Immediate Availability of Degarelix for the Treatment of Advanced Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Oct 2008
Abbott's HUMIRA(R) (adalimumab) Data Shows Fistula Healing for Up to Three Years in Patients with Moderate to Severe Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 18 Sep 2008
Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 5 Aug 2008
Panacea Pharmaceuticals Announces Appointment of Suzanne Sensabaugh as Vice President, Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jul 2008
Final Results From Phase 2 Clinical Trial of GVAX Immunotherapy for Prostate Cancer Published in the American Cancer Society's Journal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Jul 2008
Misonix Announces New Distribution Agreement for Sonablate(R) in the Russian Federation
Devices Distribution
 HSMN NewsFeed - 27 Jun 2008
ABC News NIGHTLINE Features HIFU with Sonablate(R) 500 as Non Invasive Treatment Option for Prostate Cancer
Devices Oncology
 HSMN NewsFeed - 2 Jun 2008
Data from Satraplatin SPARC Phase 3 Trial in Patients with Hormone-Refractory Prostate Cancer Progressing after Initial Chemotherapy Presented at 44th ASCO Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 May 2008
Aureon Laboratories Introduces Prostate Px(R)+, First Biopsy-Based Test to Predict Prostate Cancer Disease Progression and Recurrence
Diagnostics Urology Oncology
 HSMN NewsFeed - 6 May 2008
Prostate Cancer Breakthrough Receives FDA Clearance
Devices Urology FDA
 HSMN NewsFeed - 30 Apr 2008
FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceutical's TRELSTAR(R) DEPOT and TRELSTAR(R) LA
Biopharmaceuticals Devices Drug Delivery Oncology FDA
 HSMN NewsFeed - 16 Apr 2008
Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 1 Apr 2008
DiagnoCure provides update on operations
Diagnostics
 HSMN NewsFeed - 27 Mar 2008
Positive Phase III Data Unveiled for New GnRH Blocker Degarelix
Biopharmaceuticals Urology
 HSMN NewsFeed - 19 Mar 2008
New Study Backs use of Gene-Based Urine Test in Prostate Cancer
Diagnostics Oncology Urology
 HSMN NewsFeed - 12 Feb 2008
CyberKnife Users' Meeting Highlights Major Clinical Data Milestones and Emerging Trends
Devices Oncology
 HSMN NewsFeed - 20 Dec 2007
Abbott's HUMIRA(R) Approved in the European Union for Treatment of Moderate-to-Severe Plaque Psoriasis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 13 Dec 2007
EDAP Announces First Published Long-Term Study of HIFU for Localized Prostate Cancer
Devices Oncology Urology
 HSMN NewsFeed - 16 Nov 2007
Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 6 Nov 2007
REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
Biopharmaceuticals
 HSMN NewsFeed - 17 Oct 2007
Hyperthermia Combined with Radiation and Androgen Therapy Provides Positive Results with Reduced Toxicity for Prostate Cancer Treatments
Devices Oncology
 HSMN NewsFeed - 15 Oct 2007
Clinical Studies Show REMICADE Reduces Incidence of Bowel Surgeries in Ulcerative Colitis Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 14 Aug 2007
Misonix Highlights Recent Duke University Study Revealing Significant New Cancer Treatment May Be Possible with HIFU Technology
Devices Oncology
 HSMN NewsFeed - 8 Aug 2007
CyberKnife(R) System Extracranial Treatments Grow 75 Percent in Fiscal Year 2007 Demonstrating Radiosurgery Market Shift
Devices Oncology
 HSMN NewsFeed - 17 Jul 2007
Panacea Pharmaceuticals Announces the Availability of LC Detect(sm), a Serum-Based Diagnostic Test for Lung Cancer
Diagnostics Oncology
 HSMN NewsFeed - 15 Jun 2007
REMICADE(R) Two Year Data in Ankylosing Spondylitis Show Improvement in Spinal Mobility and Spinal Inflammation
Biopharmaceuticals
 HSMN NewsFeed - 15 Jun 2007
Three Studies Suggest Abbott's HUMIRA(R) (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 7 Jun 2007
Abbott's HUMIRA(R) (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 7 Jun 2007
Remicade(R) Receives EU Approval as First and Only Biologic Treatment for Pediatric Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 5 Jun 2007
Misonix Announces FDA Clinical Trial Enrollment Acceleration for Sonablate 500 HIFU Treatment of Prostate Cancer
Devices Oncology
 HSMN NewsFeed - 4 Jun 2007
Updated Study Results Reinforce Survival Benefit of Taxotere(R) (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2007
Panacea Pharmaceuticals Announces the Availability of PC Detect(sm) for Prostate Cancer Screening
Diagnostics Oncology
 HSMN NewsFeed - 22 May 2007
Outcomes Data Continue to Demonstrate Value of Cytogen's PROSTASCINT(R) to Predict Prognosis in Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 May 2007
Ablatherm-HIFU Adoption Growing Across Europe
Devices Oncology
 HSMN NewsFeed - 9 May 2007
Ablatherm-HIFU Localized Prostate Cancer Clinical Study Resumes at Virginia Urology Center
Devices Oncology
 HSMN NewsFeed - 7 May 2007
Abbott Seeks U.S. and E.U. Regulatory Approvals for HUMIRA(R) (Adalimumab) as a Treatment for Juvenile Rheumatoid Arthritis
Biopharmaceuticals FDA Regulatory
 HSMN NewsFeed - 30 Apr 2007
New Study Shows That Cesium-131 From IsoRay Medical(TM) Is an Effective, Well-Tolerated Brachytherapy Treatment for Prostate Cancer with Fewer Side Effects Than Other Medical Isotopes
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Apr 2007
Cesium-131 From IsoRay Medical (TM), Inc. Established as a Front Line Treatment for Early Stage Prostate Cancer Treatment in a Recent Clinical Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Apr 2007
Abbott's HUMIRA(R) (Adalimumab) Receives Positive Opinion from European Medicines Agency for the Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 10 Apr 2007
Abbott Opens New Biotechnology Manufacturing Facility in Puerto Rico
Biopharmaceuticals
 HSMN NewsFeed - 2 Apr 2007
Abbott Seeks U.S. and E.U. Regulatory Approval for HUMIRA(R) (Adalimumab) in Psoriasis
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 26 Mar 2007
European Union CHMP Recommends Approval of First and Only Biologic Treatment for Pediatric Crohn's Disease: REMICADE(R)
Biopharmaceuticals Regulatory Gastroenterology
 HSMN NewsFeed - 22 Mar 2007
Satraplatin Phase 3 SPARC Trial - Additional Data Presented at European Association of Urology Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Mar 2007
Additional Data from Satraplatin SPARC Phase 3 Trial Presented at European Association of Urology Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Mar 2007
Miraculins Announces Positive Results in Pivotal Prostate Cancer Biomarker Study
Diagnostics Oncology
 HSMN NewsFeed - 26 Feb 2007
'Encouraging' Major Responses Seen With XYOTAX(TM) in Patients With Taxane-Resistant Androgen Independent Prostate Cancer
Biopharmaceuticals
 HSMN NewsFeed - 23 Feb 2007
Phase 2 Results of Genasense(R) Plus Chemotherapy in Advanced Prostate Cancer Reported at Cancer Conference
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Feb 2007
Misonix Enlists Experienced Sonablate(R) 500 Distributor Takai Hospital Supply to Market Leading HIFU Prostate Cancer Treatment Device in Turkey, Greece and Cyprus - First Sale Reported in Turkey
Devices Oncology Distribution
 HSMN NewsFeed - 8 Feb 2007
Seven-Year Survival Data Demonstrate use of Cytogen's PROSTASCINT(R) Independently Predicts Recurrence of Prostate Cancer
Biopharmaceuticals Radiology Oncology
 HSMN NewsFeed - 7 Feb 2007
IRIS Submits 510(k) Application To FDA For Its N.A.D.I.A. Prostate Cancer Test
Diagnostics Oncology FDA
 HSMN NewsFeed - 5 Feb 2007
British Journal of Urology Demonstrates Ablatherm Success for Late Stage Prostate Cancer Therapy
Devices Oncology
 HSMN NewsFeed - 2 Feb 2007
New Analyses Reinforce Efficacy of REMICADE(R) in Treatment of Severe Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 2 Feb 2007
REMICADE(R) Therapy Shown to Improve Productivity in Patients Treated for Chronic Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 25 Jan 2007
European Association of Nuclear Medicine Journal Article Reports New Data Regarding Administration of QUADRAMET(R) with Chemotherapy in Hormone Refractory Prostate Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Jan 2007
Misonix Brings Visually Directed HIFU for Prostate Cancer to Portugal
Devices Oncology
 HSMN NewsFeed - 4 Jan 2007
Expanded Role for Cytogen's PROSTASCINT(R) Incorporated Into NCCN(R) Clinical Practice Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Dec 2006
GTx Announces That Ostarine Achieved Primary Endpoint of Lean Body Mass and a Secondary Endpoint of Improved Functional Performance in a Phase II Clinical Trial and Reacquisition of Full Rights to GTx SARM Program
Biopharmaceuticals
 HSMN NewsFeed - 14 Nov 2006
Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval for Inhibiting Structural Joint Damage and Improving Physical Function in Patients With Psoriatic Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Nov 2006
Study Shows Ambrilia's PSP94 Immunoassay to Have Prognostic Value in Prostate Cancer Management
Biopharmaceuticals Diagnostics Oncology Urology
 HSMN NewsFeed - 1 Nov 2006
Cellgate Commences Phase II Clinical Trial of Anticancer Compound CGC-11047 for Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Oct 2006
Misonix Brings Visually Directed HIFU for Prostate Cancer Treatment to Spain
Devices Oncology
 HSMN NewsFeed - 23 Oct 2006
New Phase III Data Shows Abbott's HUMIRA(R) (Adalimumab) Induced Clinical Remission In Patients With Crohn's Disease Who Lost Response to, or Were Intolerant to, Remicade(R) (Infliximab)
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Oct 2006
Data Show Treatment With Remicade(R) Reduced Hospitalizations for Ulcerative Colitis Patients By Half
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 19 Oct 2006
FDA Expands REMICADE(R) Indication for Ulcerative Colitis: Biologic Maintains Long-Term Clinical Remission and Mucosal Healing
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 5 Oct 2006
New Phase III Data Show Abbott's HUMIRA(R) (Adalimumab) Was Statistically Superior to Methotrexate in Patients With Psoriasis
Biopharmaceuticals
 HSMN NewsFeed - 2 Oct 2006
Final Data From Two Phase II Trials Indicate Activity of Adecatumumab (MT201) in Breast and Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Sep 2006
Published Study Shows Focal Cryoablation Effective in Destroying Prostate Cancer, Preserving Potency, Continence
Devices Oncology
 HSMN NewsFeed - 27 Sep 2006
FDA Approves REMICADE(R) for Treatment of Chronic Severe Plaque Psoriasis: Marks Major Milestone for Patients With High Disease Burden
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Sep 2006
Final data from Antisoma's AS1404 lung cancer trial show clear survival benefit
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Sep 2006
EntreMed Commences Panzem(R) NCD Phase 2 Study in Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2006
Misonix Reports: Influential Urologists From Around the World Speak of the Benefits of the Sonablate(R) 500 at the 6th Annual SB500 User Group Meeting at the AUA Conference
Devices Oncology Urology
 HSMN NewsFeed - 24 May 2006
New Analysis Showed Ulcerative Colitis Patients in Clinical Remission Had Higher Rates of Employment and Lower Rates of Disability
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 22 May 2006
Matritech's NMP22(R) BladderChek(R) Test Could Save Lives and Reduce Expense in Screening High Risk Populations for Bladder Cancer
Diagnostics Oncology
 HSMN NewsFeed - 22 May 2006
New Study Demonstrates That Prostate-Specific Membrane Antigen (PSMA) Expression Predicts Prostate Cancer Recurrence
Diagnostics Urology Oncology
 HSMN NewsFeed - 22 May 2006
Prostate-Specific Membrane Antigen (PSMA) Expression in Neovasculature Associated with Renal Cell Carcinoma is Characterized
Diagnostics Oncology Urology
 HSMN NewsFeed - 16 May 2006
Abbott Enters Agreement With Advanced Life Science Institute to Develop Lung Cancer Test
Diagnostics Oncology
 HSMN NewsFeed - 8 May 2006
Cytogen Announces FDA Clears IND for CYT-500, a Monoclonal Antibody for the Treatment of Metastatic Hormone-Refractory Prostate Cancer
Biopharmaceuticals Oncology FDA
Return to NewsFeed  

 Additional items found! 159

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 159 additional stories matching:
PsA
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!